Should You Sell Your Dental Practice to a DSO? How to Evaluate the Offer (2026)

Last updated: August 2026

I'm Sean Yu, co-founder of Peony. Before Peony I spent my career on the deal side, and one of the most emotionally loaded conversations I have is with a dentist who has just had a DSO land an offer on their desk. It is usually framed as a "partnership," the headline multiple sounds enormous relative to what they thought their practice was worth, and there is often more than one DSO circling at once. The dentist is genuinely torn — part windfall, part guilt about the staff, part fear of signing away the thing they spent twenty years building. I run Peony, a data room company serving 6,800+ customers, so I see a lot of these processes from the inside. This post is the honest evaluation guide: how to decode what a DSO offer actually is, what the number really nets you, what happens to you and your people, and — bluntly — for whom a DSO is the right buyer and for whom it is not.

Let me say the fair part up front, because the internet is full of both DSO cheerleading and DSO horror stories and neither is the truth. Some dentists do brilliantly selling to a DSO, and some regret it — and the difference is almost always the structure, not the buyer. A "premium" DSO offer built mostly on rollover equity and an earnout can net you less than a plain private-buyer offer once every adjustment plays out. A well-negotiated DSO deal with the right platform can pay you twice — once at close and again when the platform sells. Which one you get is decided by the details below, and by whether you evaluated the offer against real competition instead of accepting the first LOI.

Quick answer. A DSO offer is not one number; it is three. Split the headline into cash at close (the only guaranteed piece, typically ~60-80% of the deal), rollover equity (~15-40%, illiquid for about 5-7 years and tied to the DSO's performance, not yours), and an earnout (the remainder, paid only if you hit targets). Then check how they recast your EBITDA, because a quality-of-earnings review can strip six figures off an over-claimed EBITDA and that, not the multiple, often decides your real price. Read the autonomy and non-compete terms against how clinical control actually works in your state — there is no federal non-compete ban anymore. And create leverage by running a real process against several DSOs at once through a confidential, per-buyer data room, comparing net-at-close plus risk-adjusted contingent value rather than the headline. For baseline valuation and the full sale process, see our dental practice sale guide.

---

Should you sell your dental practice to a DSO?

The decision is about the structure of the offer, not the headline multiple — and a "premium" DSO offer can net you less than a modest private-buyer offer once rollover, earnout, and the EBITDA recast play out. That is the single most important sentence in this guide. DSO offers are engineered to look large, because a big fraction of the number is equity you cannot sell for years and cash you only collect if performance targets are met. So the first job is never "is this a good multiple." It is "what does this number actually net me, guaranteed, on the day I sign."

Here is the honest fork. A DSO is often the right buyer when your practice fits a platform's density or specialty strategy so it will genuinely pay up, when you are comfortable practicing inside a larger system for a few more years, and when you value the "second bite" upside of rollover equity and understand it is a bet on the whole platform. A DSO is often the wrong buyer when you need the proceeds to be cash rather than paper, when your identity is bound up in running your own shop, when you are young enough that continuing to compound equity in a practice you control beats rolling into someone else's, or when the local offer market is soft and you are being rushed. Neither profile is universal, and the same offer can be excellent for one dentist and a mistake for another. The rest of this post is how to tell which one you are.

One counterweight worth internalizing before we go further: advisory analysts who model these deals side by side point out that because much of a DSO's headline price is rollover plus earnout, a "premium" DSO offer can net less than a "modest" individual-buyer offer once all the adjustments settle (Deal Prospectors). A DSO premium is real sometimes, but it is buyer-specific and never automatic (Auxo Capital Advisors). Treat the headline as marketing until you have done the arithmetic yourself.

Who are the DSOs making these offers?

The buyers are a small set of large, mostly private-equity-backed platforms, plus a handful of specialty consolidators — and knowing who owns each one tells you whose performance your rollover equity actually rides on. DSO affiliation has roughly doubled in a decade: ADA Health Policy Institute data, as reported by DentistryIQ in August 2026, shows 16.1% of U.S. dentists were affiliated with a DSO in 2024, more than double the roughly 7.4% of 2015. The shift is concentrated among younger dentists: per ADA News (November 2025), more than 1 in 4 dentists up to ten years out of school were DSO-affiliated in 2024, far higher than among long-established dentists, with Colorado and Oklahoma seeing the largest recent increases.

Here is the census. Every count is approximate and moves quarterly, so read each as "roughly, as of the cited source," and every ownership fact is written "as of" its verified date because PE ownership on these platforms is fluid.

The one structural detail I would not skip: PDS Health is founder-controlled, not majority private-equity owned (The Molar Report) — which makes it the odd one out in this list, because when you roll equity into a PE-backed platform your "second bite" depends on a fund's exit timeline, whereas a founder-controlled platform runs on a different clock. That is not automatically better or worse for you; it is a different bet, and you should know which one you are being offered. For the others, verify ownership yourself from the primary source before you sign — for example Warburg Pincus's own release on the MB2 recapitalization, Leonard Green's release on Aspen, Mubadala's announcement on DCA, Gryphon's announcement on Smile Brands, Linden's and THL's pages on Smile Doctors, and USOSM's release on the Oak Hill investment.

On where all this is heading, I will give you both credible views rather than pick one, because the honest answer is that the experts disagree. Brian Colao, who directs Dykema's DSO Industry Group, predicts 75% to 80% of practices will be consolidated in ten to fifteen years. CPA Brian Hanks, using a strict definition, estimates consolidation "doesn't ever get above 20% of all dental practices" (DentistryIQ). What is not in dispute: nearly three in four U.S. dentists still own their practice, and the near-term deal market cooled — Dykema characterized 2025 as "The Year of the Muted Recovery," with the expected post-rate-cut rebound largely failing to materialize and over 50 significant DSO sale processes abandoned during the downturn. 69% of DSOs surveyed said their private-equity sponsors expect a moderate or high increase in 2026 acquisition activity, per TUSK Practice Sales' Q2 2026 Dental Market Report — read that as one industry survey signaling appetite, not a guarantee your phone keeps ringing.

What does a DSO offer actually consist of?

A DSO offer breaks into three buckets — cash at close, rollover equity, and an earnout — and only the cash at close is guaranteed money on signing day. Advisory norms for 2025 to 2026 put a typical DSO deal at roughly 60% to 80% cash at close, 15% to 40% rollover or retained equity, with the remainder in earnouts tied to performance over one to three years; most DSOs require sellers to reinvest about 10% to 30% of proceeds back into acquirer equity (Deal Prospectors; Scott Leune). The earnout is performance-contingent, tied to retained EBITDA or production targets, commonly over 12 to 36 months with 24 months most typical, and paid only if targets are hit. So the headline "enterprise value" is a blend of guaranteed cash, illiquid paper, and a maybe.

Let me make that concrete. The numbers below are illustrative — I picked a round headline and applied only the pack's published ranges to it; your real split will differ, and you should run this exact exercise with your own LOI.

Take an illustrative 2,000,000 dollar DSO offer. Convert it into the three buckets using the norms above:

• Guaranteed — cash at close. At the range's midpoint of about 70%, that is roughly 1,400,000 dollars you actually receive at closing. At the low end (60%) it is 1,200,000 dollars; at the high end (80%) it is 1,600,000 dollars. This is the only bucket you can bank.
• Illiquid — rollover equity. Say you roll about 20% of the deal into acquirer equity: that is 400,000 dollars of value on paper, locked up for roughly five to seven years and worth whatever the DSO is worth when it next sells — could be more, could be less, could be diluted.
• Contingent — earnout. The remainder, about 10% here, is 200,000 dollars you collect only if you hit the EBITDA or production targets over the earnout window. Miss them and this bucket shrinks or disappears.

So a "2 million dollar" offer, on these illustrative midpoints, is really about 1.4 million guaranteed, 400,000 in a multi-year bet on the platform, and 200,000 you have to earn. Now compare that honestly to a private buyer offering, say, 1.6 million all cash. The DSO's headline is 25% higher, but its guaranteed cash is lower. That is not a reason to reject the DSO — the rollover could pay off handsomely — but it is exactly why you never compare headlines. You compare guaranteed cash at close first, then risk-adjust the contingent and illiquid pieces separately.

How will the DSO recast your EBITDA, and why does it decide your real price?

DSOs underwrite your practice on adjusted EBITDA under their own operating framework, not on your trailing books — and the recast, more than the multiple, is what sets your real price. A DSO buying your practice is not paying for what you earned; it is paying a multiple of what it believes the practice will earn as a normalized asset inside its system (Auxo; Scott Leune). That means two things happen to your number. First, they normalize your compensation to a market associate salary and rebuild EBITDA from there. Second, and this is where deals get retraded, their quality-of-earnings review strips out add-backs you cannot document.

The size of that swing is not small. Buyers routinely "strip aggressive add-backs, retrade on undisclosed liabilities, and adjust price for retention risk" (Dental Transitions), and it is routine for a QoE review to knock six figures off an over-claimed adjusted EBITDA. As an illustrative case: claim 1.1 million dollars, document only 800,000, and the 300,000 a buyer strikes becomes 1.8 million dollars of price at a 6x multiple. Multiply any haircut by the deal multiple and you can see a seven-figure gap open between the number in the LOI and the number at close. This is why the multiple headline lies: a smaller multiple on an EBITDA you can defend beats a bigger multiple on an EBITDA that evaporates in diligence.

Your defense is documentation. Every add-back — owner's above-market pay normalized to replacement salary, genuine one-time expenses, personal costs run through the practice, related-party rent — needs a paper trail a buyer's accountant can confirm, because an add-back you cannot support is one they will strike. Get this work done before you show a number. The mechanics of building and defending a quality-of-earnings package are their own subject — our quality of earnings guide covers how buyers test the number and how to prepare for it, and the preparation and normalization steps live in the dental practice sale guide. Walk in with a defensible EBITDA and the recast becomes a verification; walk in with a padded one and it becomes a price cut.

What is rollover equity actually worth?

Rollover equity is typically 10 to 30 percent of deal value, occasionally up to 40 percent, and it is genuinely worth something — but it is illiquid for about five to seven years and tied to the whole DSO's performance, not your practice's. This is the "second bite at the apple," and it is the most misunderstood part of a DSO offer. The pitch is that when the DSO recapitalizes or sells to the next buyer in roughly three to seven years at a higher multiple, your retained stake gets marked up and you collect again (Deal Prospectors; Dental Wealth Partners). That is real, and dentists who rolled into platforms that kept compounding have done extremely well on the second bite. I am not going to talk you out of it.

But be clear-eyed about two things. First, it is illiquid — you cannot sell it, you cannot spend it, and you are locked in for the hold period whether or not you still want to be there. Second, its value rides on the DSO's leverage and performance across every practice it owns, not on how well your office does. If the platform stumbles, takes on too much debt, or the next recapitalization comes at a lower multiple, your paper can be diluted or worth far less than the LOI implied. It is upside, but it is venture-style upside, and you should size it as a bet, not as cash.

Which equity you actually receive matters enormously, and there are two dominant models (Dental Wealth Partners). In a holdco model you roll into the parent DSO's equity, so your return depends on the entire platform. In a joint venture (JV) model you retain equity at the subsidiary or practice level — a structure explicitly used by consolidators like Specialty1 Partners — so your return tracks a smaller, more local pool. Neither is strictly better; they are different risk profiles, and you need to know which one is on the table. Before you sign, get answers in writing to a specific list: which entity's shares are these, is there any distribution history, how does dilution work in the next financing, what happens to my equity on death or disability, and when is the next recapitalization actually expected? If the buyer cannot or will not answer those, treat the rollover as worth close to zero in your comparison until they do. The same second-bite logic drives every private-equity roll-up — our roll-up data room guide covers how these platforms aggregate and re-sell, which is worth understanding when your payout depends on their next exit.

What happens to you and your staff after the sale?

You typically commit to keep practicing for about two to five years on a base plus production, your office integrates into the platform over the first 12 to 24 months, and your staff are protected only to the extent it is written into the deal. Start with your own role, because it is more constrained than sellers expect. Selling dentists commonly agree to a continued-employment commitment of roughly two to five years — and note Dental Transitions reports most DSO affiliations ask for a five-year minimum work-back — and post-sale compensation is typically a base of around 200,000 to 400,000 dollars plus production bonuses, often expressed as a percentage of collections or production (Deal Prospectors). Full integration into the platform's systems and processes usually runs over the first 12 to 24 months post-close. So this is not a walk-away sale; it is a sale plus a job, and you should evaluate the job — the comp formula, the production expectations, the reporting lines — as seriously as the price.

Now your staff, because this is the part that keeps good owners up at night, and rightly so. The practical reality is that most DSOs keep the clinical and front-desk team, because the production a buyer paid for depends on those people staying. What changes, usually over that 12-to-24-month integration, is behind the scenes at first — payroll and benefits administration, some vendors and software, scheduling and reporting systems. The honest caution is this: staff protections are contractual only if they are written into the purchase agreement. A verbal "we love your team, nothing will change" in a management meeting is worth exactly nothing when integration decisions get made later. So decide what matters to you — team retention, comp-protection periods for key people, which vendors and systems change and on what timeline — and negotiate those into the documents. What is negotiable here is broader than most sellers realize, but only if you raise it before you sign. A promise that is not in the contract is a hope, not a protection.

What are the red flags in a DSO offer?

The red flags are structural, not villainous — an earnout-heavy mix, an unauditable recast, vague autonomy language, an overreaching non-compete, equity with no distribution history, and pressure tactics — and spotting them means slowing down, not walking away. Let me take the ones that matter most.

• A consideration mix tilted toward earnout. Since only cash at close is guaranteed, an offer that pushes value into the earnout is shifting risk onto you. A high headline with low guaranteed cash is a flag to negotiate the mix, not necessarily to reject the deal.
• An EBITDA recast you cannot audit. If you cannot reproduce the buyer's adjusted-EBITDA number from your own books, you cannot defend your price. Aggressive recasts are where deals get retraded; insist on seeing the buildup.
• Vague autonomy language that does not match clinical reality. DSOs operate around the corporate-practice-of-dentistry doctrine, under which non-dentists generally may not own or control clinical decision-making — so a DSO owns only the non-clinical, management side (Hendershot Cowart). But the doctrine varies substantially by state: some enforce strictly, others permit broad DSO involvement. California, for example, tightened this in October 2025 (effective January 1, 2026) with a new law formalizing restrictions on private-equity and hedge-fund-operated physician and dentist management platforms (Sidley); Colorado has enacted stricter regulations over DSO involvement; Texas bars non-dentist control of treatment while accommodating the management side. Read the offer's promises about your clinical control against how your state actually treats the split, and have a healthcare attorney do the same.
• A non-compete that could lock you out of your own market. This one moved recently, so ignore old advice. There is no federal non-compete ban — the FTC's 2024 Non-Compete Rule never took effect, and after a Texas court set it aside, the FTC on September 5, 2025 moved to accede to vacatur and drop its defense of the rule. So state law governs, and it is a patchwork: Colorado's 2025 law bans non-competes for healthcare providers including dentists, and Texas enacted a law on June 20, 2025 (effective September 1, 2025) that, for the first time, extends non-compete restrictions to dentists (Littler). Check what your state actually allows before you accept any restrictive covenant.
• Equity with no distribution history, and pressure tactics. Rollover shares with no record of distributions deserve skepticism. And an "exploding" LOI that gives you days to sign is a pressure tactic designed to stop you from running a process — which is the one thing that would protect you.

None of these makes a DSO a bad buyer. They are the reasons to get the number audited, read the covenants with a healthcare M&A attorney, and refuse to sign anything exclusive until you have.

How do you negotiate a DSO offer, and how do you compare several?

Your leverage is a real process with several bidders, and the way you compare them is net cash at close plus risk-adjusted contingent value — never the headline. A single DSO that knows it is the only buyer at the table has no reason to improve its offer. Three DSOs that know they are competing do. So the highest-return move you can make is to quietly run a process: get several credible buyers looking at the same financials at the same time, and let the competition set the price. Everything about a DSO's structure — the recast, the mix, the rollover terms — is more negotiable when there is a bidder behind you.

To compare offers honestly, model each one in three cases — conservative, base, and upside — rather than trusting a single headline:

• Guaranteed layer: cash at close, net of fees and taxes. This is apples-to-apples across every offer and it is where you start.
• Contingent layer: the earnout, discounted for the probability you actually hit the targets. A 300,000 dollar earnout you are 50/50 to earn is not worth 300,000 dollars.
• Illiquid layer: the rollover, sized as a bet on that specific platform given its ownership, leverage, and distribution history — not booked at face value.

Then, and only then, do you know which offer is actually the strongest. Often the highest headline is not the highest risk-adjusted value.

The operational problem is that running several DSOs in parallel means several buyers reading your P&L at once, and if that leaks to your staff or a competitor-adjacent buyer, you damage the very thing you are selling. The tool for that is a confidential data room with a separate link per buyer, an NDA gate, per-viewer watermarks, and engagement analytics that show you which DSO actually read the financials versus which one is fishing. That is a natural home for Peony — it is the confidential quiet-sale mechanic, and the clinic sale data room guide walks through the full staged-reveal playbook that applies just as well to a dental practice. One timing point makes all of this urgent: a DSO LOI typically locks you into exclusivity for 60 to 120 days (Dental Transitions), which means the moment you sign one, you have chosen a single buyer and given up the others. Choose with evidence — run the competition before you sign, not after.

When should you not sell to a DSO?

Do not sell to a DSO when you have more equity to compound on your own, when your practice has pricing power a rushed sale would undersell, when your identity is tied to autonomy, or when the offer market is weak — and remember the alternatives are not only "DSO or nothing." The clearest case is the younger owner. If you have a decade or two of runway, continuing to build and eventually sell a practice you fully control can create more wealth than rolling into someone else's platform early and watching your rollover ride their timeline. Selling young trades a compounding asset you own for illiquid paper you do not.

The next case is the strong, differentiated practice. A practice with genuine pricing power — a solid fee-for-service mix rather than heavy PPO dependence, an associate bench you already built, systematized operations — has leverage that a fast DSO process can leave on the table. That kind of practice can often command a better outcome by waiting for the right buyer or the right market than by taking the first platform offer. Related, if your satisfaction is bound up in running your own shop your way, the honest truth is that operating inside a platform model for two-to-five years post-sale is a poor fit for some people regardless of the check, and no amount of money fixes a daily reality you dislike. And in a soft offer market — the kind of "muted recovery" the industry saw in 2025 — the right answer can simply be to wait.

Finally, remember the menu is wider than the LOI on your desk. An associate buy-in that transitions the practice to someone already inside it, or a straight private-buyer sale, may fit your goals better than any DSO deal — and each carries a different tax and process path. Those alternatives, along with baseline valuation methodology, the full sale timeline, and tax structure, are the subject of our dental practice sale guide; this post deliberately stays inside the DSO offer, and the guide owns the rest of the decision. If you are weighing an advisor to run whichever path you choose, our best healthcare M&A advisors rundown is where to start, and for a sense of how sophisticated buyers diligence a healthcare business — which is what a DSO will do to yours — the healthcare due diligence and private equity due diligence guides map the process. Independent sponsors buy in this space too, and how they raise deal-by-deal capital is covered in our independent sponsor healthcare capital partners piece.

Frequently asked questions

Is a DSO offer worth it?

Sometimes, and the answer lives in the structure, not the headline number. A typical DSO deal is roughly 60 to 80 percent cash at close, 15 to 40 percent rollover equity you cannot sell for about five to seven years, and the remainder in an earnout you only collect if you hit targets. Only the cash at close is guaranteed. Because so much of a DSO's "premium" sits in rollover and earnout, a headline that beats a private buyer can net you less once the adjustments play out. It is worth it when the density strategy, the equity terms, and the post-sale role genuinely fit you, and when you got there by running a real process against several bidders rather than accepting the first LOI. It is not worth it when the number is mostly contingent paper and you needed cash. Model the guaranteed, contingent, and illiquid pieces separately before you decide.

How do DSOs value a dental practice?

DSOs underwrite on adjusted EBITDA and apply a multiple that rises with size. Advisory bands for 2025 to 2026 run roughly 5x to 7x adjusted EBITDA for a single-doctor tuck-in, about 7x to 9x for associate-led groups, and 10x to 12x or more for platform-grade groups above 5 million dollars of EBITDA. The multiple is only half the math. The bigger swing is how they recast your EBITDA: DSOs often underwrite earnings "as they would be under their operating framework," strip add-backs they cannot document, and it is routine for a quality-of-earnings review to knock six figures off an over-claimed number: an add-back schedule claiming 1.1 million dollars of EBITDA that supports only 800,000 loses 300,000, and at a 6x multiple that is 1.8 million dollars of price. A smaller multiple on a defensible EBITDA can beat a bigger multiple on a number that gets retraded in diligence. Baseline valuation methodology sits in our dental practice sale guide; this post is about what the DSO does to it.

Is DSO rollover equity worth anything?

It can be worth a great deal or very little, and you cannot tell from the offer letter. Rollover equity is typically 10 to 30 percent of deal value, sometimes up to 40 percent, and it is illiquid for about five to seven years until the DSO recapitalizes or sells to the next buyer at, ideally, a higher multiple. The "second bite at the apple" is real upside for sellers who joined a platform that kept compounding. But the equity is tied to the whole DSO's leverage and performance, not your practice, and it can be diluted or worth nothing if the platform stumbles. Ask which entity's shares you get (parent holdco or a practice-level joint venture), whether there is a distribution history, how dilution works, what happens on death or disability, and when the next recapitalization is expected. Treat it as venture-style upside, not as cash.

What happens to my staff if I sell to a DSO?

Legally, nothing is protected unless it is written into the deal. In practice most DSOs retain the clinical and front-desk team because the practice's production depends on them, and they fold the office into the platform's systems over the first 12 to 24 months. What changes is usually behind the scenes at first: payroll, benefits, some vendors and software, and reporting. What is negotiable, and what you should negotiate, is staff retention, comp-protection periods, and which systems and vendors change and when. If keeping your team whole matters to you, get those commitments in the purchase agreement rather than trusting a verbal assurance in a management meeting. A promise that is not in the contract is not a protection; it is a hope. Your own post-sale role usually comes with a two-to-five-year commitment and a base plus production.

What are the red flags in a DSO offer?

Watch for a consideration mix that is heavy on earnout and light on cash at close, since only the cash is guaranteed. Watch for an aggressive EBITDA recast you cannot audit or reproduce from your own books. Watch for vague autonomy language that does not match how clinical control actually works in your state, and for non-compete terms that could keep you out of your own market. There is no federal non-compete ban: the FTC's 2024 rule never took effect and, as of September 2025, the agency moved to drop its defense of it, so state law governs, and the rules vary widely. Also watch for equity with no distribution history, and for pressure tactics like an exploding LOI that gives you days to sign. None of these means the buyer is bad. They mean you slow down, get the number audited, and read the fine print with a healthcare M&A attorney before you sign anything exclusive.

How do I compare offers from multiple DSOs without the process leaking to my staff or competitors?

Run every bidder through one confidential data room with a separate link per buyer, so you can see each DSO's activity on its own and shut any one of them out without touching the others. Gate the room behind an NDA, serve the P&L view-only with each viewer's name watermarked across the page, and use the engagement analytics to see which DSO actually read the financials versus which one is fishing. That behavioral data is real negotiating leverage. I run Peony, a data room company serving 6,800+ customers, and this is exactly the job it is built for: per-viewer dynamic watermarking is on the 52-dollar-per-admin-per-month Data Room plan, the 30-dollar Business plan covers a lighter process, and the free tier lets you try the workflow before you commit. Analytics, link expiry, and revoke are on every tier, viewers are always free, and you can run unlimited rooms, so bidding out several DSOs costs no more than one.

How long does a DSO deal take to close, and how long do I have to keep working?

A DSO transaction typically runs about six to nine months from preparing your practice for market to close — the active market-to-close phase alone commonly runs three to six months, and preparation adds the rest — and that excludes the post-close employment period. From a signed letter of intent to close is commonly 60 to 120 days, and the LOI usually locks you into exclusivity for that same 60-to-120-day window, so once you sign it you have chosen one buyer and cannot shop the others. Buyer due diligence itself runs roughly 90 to 120 days. After close, selling dentists usually commit to keep practicing for about two to five years, with full integration into the platform's model over the first 12 to 24 months, and post-sale compensation typically means a base around 200,000 to 400,000 dollars plus production bonuses. Line all of that up before you sign, because exclusivity is the moment your leverage drops.

When should you not sell to a DSO?

When the math or your circumstances point the other way. A younger owner with years of runway can often build more value by continuing to grow equity in a practice they control than by rolling into someone else's platform early. A practice with real pricing power, a strong fee-for-service mix, or an associate bench you have already built has leverage that a rushed DSO sale can undersell. If your identity and satisfaction are tied to running your own shop, the post-sale reality of operating inside a platform model can be a poor fit regardless of the check. And in a weak offer market, the right move can be to wait rather than accept a discounted number. The alternatives are not only "DSO or nothing": an associate buy-in or a private-buyer sale may fit better, and our dental practice sale guide walks through those paths.

---

About the author: Sean Yu is the co-founder of Peony, the data room platform used by 6,800+ customers across M&A, fundraising, and diligence workflows — including dentists and healthcare owners evaluating DSO and private-buyer offers. Before Peony, Sean spent his career on the deal side — M&A at Nomura, early-stage VC at Backed VC, and growth-equity / secondaries at Target Global — running and supporting sell-side and buy-side processes across healthcare, software, and industrials in North America and Europe. He studied Biomedical Engineering at Imperial College London on a full scholarship before dropping out to build companies. Sean is also a co-founder of Gingercontrol, an AI-native trade-compliance platform that raised $2.1M. Contact: sean@peony.ink • LinkedIn.

Sources

• Deal Prospectors — DSO Acquisition Offers: What Dentists Get Paid in 2026
• Deal Prospectors — Dental Practice Valuation: EBITDA Multiples by Size (2026)
• Auxo Capital Advisors — Dental Practice Valuation Multiples: 2026 Guide
• Scott Leune — DSO Acquisition Valuation Framework
• Dental Wealth Partners — DSO Deal Structures & Buyout Models Explained
• Dental Transitions — DSO Dental Practice Transition Timeline (2026)
• Dental Transitions — Dental Practice Sale Multiples: 2026 Valuation Guide
• ADA News — HPI: More new dentists affiliated with DSOs (Nov 2025)
• DentistryIQ — Is dentistry really 35% consolidated? Let's check the math
• Dykema — M&A Sector Spotlight: Dental Service Organizations (2025)
• FTC — Files to accede to vacatur of Non-Compete Clause Rule (Sept 2025)
• Sidley Austin — Newly enacted California law formalizes corporate-practice restrictions (Oct 2025)
• Littler — States continue to limit restrictive covenants for health-care professionals
• Warburg Pincus — MB2 Dental recapitalization with Warburg Pincus (Nov 2024)
• Leonard Green & Partners — Ares and Leonard Green increase ownership in Aspen Dental
• Mubadala — Mubadala acquires Dental Care Alliance
• Gryphon Investors — Gryphon Investors acquires Smile Brands
• Linden Capital Partners — Smile Doctors
• Thomas H. Lee Partners — Smile Doctors
• U.S. Oral Surgery Management — Oak Hill Capital partners with USOSM

Related resources

• Dental practice sale guide — baseline valuation, the full sale process and timeline, tax structure, and the associate path; the companion to this DSO-specific post
• Clinic sale data room — the confidential staged-reveal playbook for running a quiet sale to several buyers at once
• Quality of earnings — how buyers test your adjusted EBITDA and how to prepare a defensible add-back package
• Roll-up data room — how private-equity platforms aggregate and re-sell, which is what your rollover equity ultimately rides on
• Best healthcare M&A advisors — how to choose the advisor or broker to run your process, whichever path you pick
• Healthcare due diligence — what sophisticated healthcare buyers verify in diligence, so you can prepare for what a DSO will do to your practice
• Independent sponsor healthcare capital partners — how deal-by-deal buyers raise capital, another buyer type circling healthcare practices